Background. Allogeneic-HCT recipients are at increased risk for varicella zoster virus (VZV) reactivation and associated complications. Prevalence, timing, and risk factors for severe HZ are uncertain in the era of acyclovir (ACV) prophylaxis. Identification of patients at risk for severe HZ can help target need for prolonged prophylaxis or vaccine administration. In this study, we characterized HZ infection requiring hospitalization in a cohort of allogeneic HCT recipients.
Development and Validation of a Cycle-Specific Risk Score for Febrile Neutropenia After Chemotherapy in Patients with
Background. Prediction of febrile neutropenia (FN) with initiation of preventive measures in high-risk populations may lead to better outcomes in cancer treatment. We have previously developed a score to predict FN in the first cycle of chemotherapy.
1
We aimed to develop and validate a cycle-specific score to predict FN in cycles two to six as guidelines recommend assessing the risk of FN at each cycle start.
Methods. We included consecutive patients with solid cancers at Rigshospitalet, University of Copenhagen, 2010-2016. FN was defined as neutrophils <0.5 × 10 9 /L or leukocytes ≤2.0 × 10 9 /L at the time of either a blood culture sample or death. Predictors of FN were analysed using Poisson regression adjusted for repeated measurements using 2:1 random split sampling. Risk factors assessed were: FENCE risk groups, 1 sex, body surface area, Charlson Comorbidity Index score, haemoglobin, leukocyte and platelet levels, chemotherapy drugs, radiotherapy, prophylactic granulocyte colony-stimulating factors (G-CSF), previous FN or neutropenia, dose delays, dose reductions, and cycle number. Parameter estimates were scaled and summed to create the risk score.
Results. There were 324 FN events among the 4,590 patients in the derivation cohort with a median 3 (IQR 2-5) chemotherapy cycles. The FENCE risk groups 1 (0/+25/+25/+30 points for low/intermediate/high/very high risk), anaemia (+15 points), chemotherapy drugs (+9/+11 for platinums/taxanes), concurrent radiotherapy (+19 points), prophylactic G-CSF (−14 points), previous FN or neutropenia (0/+19/+43/+59 points for no neutropenia/neutropenia/1 FN event/>1 FN event in previous cycles), and cycle number (0/−9/−11/−12/−19 points for cycle 2/3/4/5/6) predicted FN. Discrimination of the CSR FENCE score was good with a Harrell's C-statistic of 0.79 (95% CI 0.77-0.82) and similar in the validation cohort (Table 1) . Numbers needed to treat with G-CSF to avoid one FN event over 21 days were 748, 121, and 34 in the low-, intermediate-, and high-risk groups, respectively.
Conclusion. We developed and validated a risk score to predict FN in cycles two to six of chemotherapy. The CSR FENCE score provides good differentiation of risk groups but needs validation. Methods. A retrospective cohort study of all pediatric oncology patients presenting with FN between July 2009-December 2016 was performed to evaluate if the depth and duration of neutropenia prior to presentation was correlated with blood stream infection (BSI), invasive fungal disease (IFD), pediatric intensive care unit (PICU) admission or length of stay (LOS). Patients were categorized into three groups based on ANC at time of presentation: <100, 100-500, and >500 cells/mL with decreasing ANC over the subsequent 48 hours. Durations of neutropenia prior to presentation were also assessed.
Results. A total of 585 FN episodes (FNEs) were identified in 265 patients presenting with 411(70%) ANC <100, 119(20%) ANC 100-500 and 55 (10%) ANC >500 with subsequent decline over 48 hours. Underlying diagnoses included ALL (32%), AML (29%), lymphoma (16%), neuroblastoma (16%) and other solid tumors (9%). In group ANC >500; 70% (39/55) of received chemotherapy within 2 weeks of presentation and 35% were s/p SCT. Rates of IFD and BSI were higher in the group with ANC > 500 with decline in 48 hours compared with ANC < 100 (OR = 5.9, P = 0.03) and ANC 100-500 (OR = 5.6, P = 0.034). Patients with ANC>500 cells/mL were significantly more likely to be admitted to the PICU (OR = 5.00, P = 0.017) and had an increased LOS (hazard ratio = 0.55, P = 0.002) when compared with the other two groups. No difference in PICU admission or mortality was found when patients presenting with fevers and ANC < 100 were compared with ANC 100-500. Neutropenia ≥7 days prior to FN was an independent risk factor for BSI (OR = 2.8, P = 0.001).
Conclusion. Pediatric patients presenting with febrile neutropenia and initial ANC >500 cells/mL with decine over 48 hours had a higher incidence of BSI, IFD, PICU admissions Clinicians should not be reassured when patients present with fever and initial ANC >500 cells/mL after undergoing recent chemotherapy if continued decline is expected. More work needs to be done to evaluate for risk factors at the time of presentation with FN to guide clinical care.
Disclosures. Background. Cytomegalovirus (CMV) remains a significant contributor to morbidity and mortality following solid-organ transplantation (SOT). While relapse after treatment completion can occur in up to 30% of patients, the effect of this on mortality is not clear. The aim of this study was to explore the impact of recurrent CMV disease on long-term survival in SOT recipients.
Methods. We performed a retrospective cohort study of heart, liver and kidney transplant recipients who completed treatment for an episode of CMV disease. Data on potential confounders were collected from the time of CMV treatment completion.
